PDB20 EMPAGLIFLOZIN VS SITAGLITPIN, SAXAGLIPTIN AND LIRAGLUTIDE IN SPAIN. A BUDGET IMPACT MODEL BASED ON THE CORE DIABETES MODEL AND CARDIOVASCULAR OUTCOMES TRIALS

Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.902
https://www.valueinhealthjournal.com/article/S1098-3015(19)33280-2/fulltext
Title : PDB20 EMPAGLIFLOZIN VS SITAGLITPIN, SAXAGLIPTIN AND LIRAGLUTIDE IN SPAIN. A BUDGET IMPACT MODEL BASED ON THE CORE DIABETES MODEL AND CARDIOVASCULAR OUTCOMES TRIALS
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)33280-2&doi=10.1016/j.jval.2019.09.902
First page :
Section Title :
Open access? : No
Section Order : 10794
Categories :
Tags :
Regions :
ViH Article Tags :